Norvasc, Amlodipine News

Pfizer Inc. , the world's largest drugmaker, said second-quarter profit more than doubled as the company cut costs and boosted sales outside the U.S., where it benefited from favorable exchange rates.

Pfizer Inc. , the world's largest drugmaker, said second-quarter profit more than doubled as the company cut costs and boosted sales outside the U.S., where it benefited from favorable exchange rates.

Dear Dr. Gott: My wife is 68 years old, a diabetic, has high blood pressure and is bothered with a constant throbbing in her head, especially in bed at night.

This is due in part to poor patient adherence to cardiovascular medications. According to a new study, Caduet Adherence Related PharmacoEconomic Value Model , published in this month's Vascular Health and Risk ...

This initiative promotes the Hartford Institute's geriatric assessment tools, www.hartfordign.org/trythis . The series will include articles and corresponding videos, all of which will be available for free ...

Ahead of Daiichi Sanko's mandatory open offer for 20-per cent shares that opens on 8 August, Ranbaxy and Pfizer today said in seperate announcements that that they had entered into an agreement to settle ...

BV Mahalakshmi Posted online: Thursday , June 05, 2008 at 0029 hrs IST Hyderabad, June 4 Hyderabad-based Matrix Laboratories Ltd has been sued by the Tokyo-based Daiichi Sankyo in a patent infringement case.

Novartis , in separate statements, said a study of black patients treated with Exforge experienced a significantly higher reduction in systolic blood pressure than those on amlodipine alone and also said a ... via Market Watch

Madam Ong is a 52-year-old lady with a twelve-year-history of hypertension and diabetes. via Lim Kit Siang

Drug behemoth Pfizer Inc. , the world's largest drug, blamed an underwhelming first quarter on the patent loss in January of a pair of stalwarts: hypertension treatment Norvasc and allergy medicine Zyrtec. via Investopedia

Pfizer Inc, the world's biggest drugmaker, said on Thursday its first-quarter profit fell 18 per cent as generic competition hurt sales of blood-pressure drug Norvasc and allergy drug Zyrtec. via Business Times

Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. via Business Wire

“These results, however, are in-line with our expectations. Since the Norvasc loss of U.S. exclusivity occurred in the first-quarter 2007, the comparisons of our 2008 to 2007 quarterly results going forward will not be significantly impacted”

Pfizer Inc.'s first-quarter profit dropped 18%, reflecting increased generic competition for such top-selling products as Norvasc, Zyrtec and Lipitor, the blue-chip drugmaker said Thursday. via MarketWatch

Apr 17, 2008 - Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. via Med Ad News

Pfizer Inc. , the world's biggest drugmaker, tumbled to its lowest price per share in more than a decade in New York trading after it missed analysts' estimates in reporting that profit plunged 18 percent. via Bloomberg

Pfizer Inc. is expected to issue a mixed first-quarter financial report early Thursday as the pharmaceutical heavyweight continues to grapple with increased generic competition for several of its biggest ... via MarketWatch

Ranbaxy Laboratories has gained the approval of the Japanese government to market its generic version of blood pressure drug amlodipine for the treatment of angina. via LabTechnologist.com

From correspondents in Maharashtra, India, 04:03 PM IST The Japanese ministry of health and labour welfare has granted marketing approval to Indian pharma major Ranbaxy Laboratories Ltd's generic drug ... via India eNews

“If you look at the totality of all the trials that have been done, the results are mixed. And right now the state of knowledge is that it is lowering blood pressure, not how you get there, that's the more important thing”

A tablet that contains two different types of blood-pressure-lowering medications cuts the risk of heart attack , stroke , or death by one-fifth, when compared with an older combination drug, researchers ... via WebMD Health News

“These ACCOMPLISH results shake the foundations of current recommendations and define a new standard which will enhance the achievement of the primary goal and assist clinicians in meeting the daily challenges of hypertension management”

An international blood pressure study comparing two single-pill drug combinations has yielded results so significant that the study has been stopped early - and the researchers say their findings might alter ... via EurekAlert!